To arrange an interview, please contact the NHLBI Communications Office at 301-496-4236 or firstname.lastname@example.org.
David A. Lathrop, Ph.D., joined the National Heart, Lung, and Blood Institute (NHLBI) in 1997. Since 2011 he has served as Chief of the Heart Failure and Arrhythmias Branch in the Pediatric and Adult Cardiovascular Research Program of the Division of Cardiovascular Diseases.
Dr. Lathrop earned M.S. and Ph.D. degrees in Medical Physiology from Indiana University in 1972 and 1975, respectively. He subsequently performed postdoctoral fellowships in Cardiology at the Krannert Institute of Cardiology in Indianapolis, the University of Chicago, and the University of Cincinnati. After completing his fellowship with the University of Cincinnati, Dr. Lathrop maintained joint appointments there in the departments of Pediatrics (Cardiology) and Pharmacology and Cell Biophysics. In 1990, he became professor of Medical Physiology at the University of Tromso in Norway. When Dr. Lathrop joined NHLBI in 1997, he also maintained an adjunct professorship in Pharmacology at Georgetown University, a position he continued until 2002. From 2001 to 2002, he served as Acting Leader, Bioengineering and Genomic Applications Science Research Group, in the Clinical and Molecular Medicine Program, Division of Heart and Vascular Diseases, NHLBI, and from 2001 to 2003 Dr. Lathrop served as Assistant Director of the Clinical and Molecular Medicine Program.
Dr. Lathrop has published over 85 articles that have appeared in peer-reviewed publications. He is a member of both the American Heart Association and the Cardiac Electrophysiology Society.
Areas of Expertise: Heart failure and arrhythmias, sudden cardiac death, myocardial protection from ischemic insult, and resuscitation sciences.
November 29, 2012
: Boston Scientific
Boston Scientific to Acquire Rhythmia Medical, Inc.
Boston Scientific Corporation entered into an agreement to acquire privately-held Rhythmia Medical, Inc., a developer of next-generation mapping and navigation tools to better detect and treat abnormal heart beats, or cardiac arrhythmias. Rhythmia Medical, Inc. developed this innovative technology that measures the heart's electrical activity with support from a small business innovative research grant from the National Heart, Lung, and Blood Institute.
July 5, 2012
Obesity reported to improve heart failure outcome
"The study provides us with more insight about how both genders of heart failure patients may be impacted by the obesity paradox," noted senior author Dr. Tamara Horwich, an assistant professor of cardiology at the David Geffen School of Medicine at UCLA. He added, "Heart failure may prove to be one of the few health conditions where extra weight may prove to be protective."